Bioluminescent Reporter Assays – Applications for the Development of Cell- & Antibody-based Immunotherapies

Immunotherapies (e.g. TCR-T, CAR-T, mAbs, and bispecific Abs) hold high promise for the treatment of various diseases. These drugs stimulate a patient’s own immune system to recognize and kill tumor/infected cells. Here we introduce a versatile suite of bioluminescent reporter assays to quantitatively assess early (e.g. receptor activation) as well as late events (e.g. target cell killing) triggered by immunotherapeutic drugs.


Erik Bonke (Application Specialist) /Promega Corporation

Friday, March 24, 12:00-12:45

Registration is required. All conference participants will receive a link for a doodle registration in due time.

Go back